• 1. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 5. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509

Recent Advances in the Study of Methyl 2-amino-3-(1H-pyrazol-1-yl)propanoate Dihydrochloride (CAS: 105560-99-4)

Methyl 2-amino-3-(1H-pyrazol-1-yl)propanoate dihydrochloride (CAS: 105560-99-4) is a compound of significant interest in the field of chemical biology and medicinal chemistry. Recent studies have explored its potential applications in drug discovery, particularly as a building block for the synthesis of novel bioactive molecules. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

The compound has been investigated for its role in the development of kinase inhibitors, which are crucial in targeting various diseases, including cancer and inflammatory disorders. A 2023 study published in the Journal of Medicinal Chemistry highlighted its utility as a key intermediate in the synthesis of pyrazole-based inhibitors, demonstrating promising activity against specific kinase targets. The study employed advanced computational modeling and in vitro assays to validate the compound's efficacy.

Another notable research effort, reported in Bioorganic & Medicinal Chemistry Letters, focused on the compound's pharmacokinetic properties. The study revealed that methyl 2-amino-3-(1H-pyrazol-1-yl)propanoate dihydrochloride exhibits favorable solubility and stability under physiological conditions, making it a viable candidate for further drug development. Researchers also noted its potential for modification to enhance bioavailability and target specificity.

In addition to its applications in kinase inhibition, recent work has explored the compound's role in peptide mimetics. A 2024 preprint on ChemRxiv described its incorporation into peptide backbones to modulate receptor binding affinity. This approach could pave the way for novel therapeutics targeting G-protein-coupled receptors (GPCRs), which are implicated in a wide range of diseases.

Despite these advancements, challenges remain in optimizing the compound's selectivity and reducing off-target effects. Future research directions may include structural derivatization and high-throughput screening to identify more potent analogs. Collaborative efforts between academic and industrial researchers will be essential to translate these findings into clinical applications.

In conclusion, methyl 2-amino-3-(1H-pyrazol-1-yl)propanoate dihydrochloride (CAS: 105560-99-4) represents a versatile scaffold in medicinal chemistry with broad potential. Continued investigation into its properties and applications will likely yield significant contributions to the development of next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)